Insmed (INSM) Gains from Sales and Divestitures (2012 - 2017)
Insmed (INSM) recorded quarterly Gains from Sales and Divestitures of $89194.0 in Q2 2017, up 104.79% quarter-over-quarter from $43554.0 in Q4 2016, and up 104.79% on a YoY basis from $43554.0 in Q2 2016.
Insmed (INSM) Gains from Sales and Divestitures (2012 - 2017) Analysis & Trends
Insmed's Gains from Sales and Divestitures history runs 6 years deep, the most recent figure standing at $89194.0 for Q2 2017.
- In Q2 2017, Gains from Sales and Divestitures rose 104.79% year-over-year to $89194.0; the TTM figure through Jun 2017 stood at $89194.0 (up 104.79% YoY), while the FY2016 annual figure was $43554.0, up 62.98% from the prior year.
- Gains from Sales and Divestitures was $89194.0 for Q2 2017 at Insmed, up from $43554.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $177316.0 in Q4 2013 to a low of $17568.0 in Q1 2015.
- Historically, Gains from Sales and Divestitures has averaged $74468.2 across 5 years, with a median of $68803.0 in 2013.
- The sharpest annual moves came in 2015 and 2016: Gains from Sales and Divestitures slumped 80.89% in 2015, then soared 147.92% in 2016.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $177316.0 in 2013, then plunged by 47.75% to $92641.0 in 2014, then slumped by 71.15% to $26724.0 in 2015, then soared by 62.98% to $43554.0 in 2016, then surged by 104.79% to $89194.0 in 2017.
- The last three Gains from Sales and Divestitures figures came in at $89194.0 (Q2 2017), $43554.0 (Q4 2016), and $43554.0 (Q3 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Insmed | 19.79 Bn | 18.57 Bn | 258.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 89,194.00 |
| Jun 30, 2017 | 89,194.00 |
| Dec 31, 2016 | 43,554.00 |
| Dec 31, 2016 | 43,554.00 |
| Sep 30, 2016 | 43,554.00 |
| Sep 30, 2016 | 43,554.00 |
| Jun 30, 2016 | 43,554.00 |
| Jun 30, 2016 | 43,554.00 |
| Mar 31, 2016 | 43,554.00 |
| Mar 31, 2016 | 43,554.00 |
| Dec 31, 2015 | 26,724.00 |
| Dec 31, 2015 | 26,724.00 |
| Sep 30, 2015 | 26,480.00 |
| Sep 30, 2015 | 26,480.00 |
| Jun 30, 2015 | 26,480.00 |
| Jun 30, 2015 | 26,480.00 |
| Mar 31, 2015 | 17,568.00 |
| Mar 31, 2015 | 17,568.00 |
| Dec 31, 2014 | 92,641.00 |
| Dec 31, 2014 | 92,641.00 |